Motion Sickness Treatment Market
Motion Sickness Treatment Market is segmented By Type (Anticholinergic, Antihistamines, Others), By Route of Administration (Transdermal, Oral), By Distribution Channel (Retail Pharmacies, Online Stores), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Motion Sickness Treatment Market Size and Growth Rate Analysis
Motion Sickness Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 3.0% during the forecast period (2022-2029). Motion sickness is a general and intricate syndrome that arises in reaction to either real or perceived motion. Its presentation can be distinctive and may comprise gastrointestinal, central nervous, and autonomic symptoms. The primary manifestation of motion sickness is commonly nausea.
Motion Sickness Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Motion Sickness Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. The Motion Sickness Treatment Market in the United States and Canada produces the utmost share. Whereas the European Motion Sickness Treatment Market is projected to continue its presence globally during the period of 2022- 2029.
Motion Sickness Treatment Market Report Scope
|
Metrics |
Details |
|
Market CAGR |
3.0% |
|
Segments Covered |
By Drug Class, By Route of Administration, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Motion Sickness Treatment Market Growth Drivers and Growth Dynamics
The growing incidences of migraine, the geriatric population, increasing travel across the world, and the research on motion sickness drive the growth of the global motion sickness treatment market.
The increasing research on motion sickness and the growing geriatric population fuel the growth of the global motion sickness treatment market.
The increasing research for new treatments and new delivery approaches for the existing treatment for motion sickness is fueling the global market growth during the forecast period. For instance, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion, sponsored by Repurposed Therapeutics, Inc. and estimated to be completed by December 2022. Similarly, a Phase 1 study for Nebulizer Delivery of Intranasal Scopolamine, sponsored by Dartmouth-Hitchcock Medical Center, is predicted to be completed by August 2026. Likewise, A Randomized, Double-Blind, Placebo-Controlled Study for Tradipitant in the Treatment of Motion Sickness by the Vanda Pharmaceuticals, Washington, DC, United States.
Furthermore, with older age, there are increased eye issues and disturbed balance. For example, decreased depth perception or muscle control sends miscues to our vestibular system, a part of the inner ear and brain responsible for keeping us in balance as we go about our lives. Therefore, with growing age, there is an increased risk of motion sickness. According to the American Academy of Family Physicians, motion sickness is common in older people. Therefore, the growing geriatric population will also drive the growth of the global motion sickness treatment market. For instance, per the WHO, in 2020, the global geriatric population was 1 billion and is estimated to reach 1.4 billion by 2030 and 2.1 billion by 2050. Thus, from the above data, it is anticipated that the increasing research and growing geriatric population will drive the global motion sickness treatment market growth during the forecast period.
The availability and increased inclination towards opting for non-pharmacological options restrain the market’s growth.
The availability and increased inclination towards opting for non-pharmacological options for motion sickness hamper the global market growth. For instance, the relaxation techniques such as meditation (focusing the mind), breathing exercises, or progressive muscle relaxation (tensing and relaxing the muscles) can help decrease nausea and vomiting.
Motion Sickness Treatment Market COVID-19 Impact
The COVID-19 pandemic has greatly impacted the global motion sickness treatment market. During the pandemic, there was a decrease in tourism, and now also, people are scared of getting infected with the virus, which has led to decreased demand for motion sickness treatment. For instance, the data from The World Tourism Organization (UNWTO) indicates that in 2019, there were over 1466.0 million international tourist arrivals which observed steep decreases in the pandemic period having only around 409.5 million international tourist arrivals during the lockdown and still now post lock down the international tourist arrivals for 2021 are nearly 446.2 million which very low compared to 2019. Therefore, negatively impacting the global motion sickness treatment market.
Motion Sickness Treatment Market Segment Analysis
Antihistaminics is assumed to command the global market throughout the forecast period (2022-2029).
Antihistaminics will dominate the global motion sickness treatment market throughout the forecast period (2022-2029). Since according to the CDC, Antihistaminics are the most commonly taken and widely known medicines for motion sickness. According to the National Health Services United Kingdom, antihistamines are medicines often used to relieve symptoms of allergies, such as hives, conjunctivitis, hay fever, and symptoms of insect stings. They're even employed to avert motion sickness and as a short-term cure for insomnia. Antihistamines generally employed for motion sickness comprise cyclizine, dimenhydrinate, meclizine, and promethazine (oral and suppository). Antihistamines exhibit prolonged action, which makes them suitable for use on long trips. Most of the antihistaminic drugs are over-the-counter, which means does not require a prescription, making them easily accessible to the general public.
Furthermore, few the antihistaminics, such as chlorpheniramine, meclizine, and promethazine, exhibit central cholinergic blocking properties and have proven efficient in treating and preventing motion sickness. Also, used alone, antihistamines rarely have severe toxic effects. Hence, from the mentioned data, it is anticipated that antihistaminics will dominate the global motion sickness treatment market during the forecast period.
Motion Sickness Treatment Market Geographical Analysis
The North American region holds the largest global motion sickness treatment market.
North America is anticipated to dominate the global market during the forecast period (2022-2029). Owing to the presence of key market players such as Prestige Brands, Inc., Baxter International, Inc., Pfizer and CVS Health holding a major share of the global motion sickness treatment market in North America, which ensures the dominance of this region over the global motion sickness treatment market. Furthermore, North America’s high number of tourists contributes to this region's dominance over the global market. For instance, The World Tourism Organization (UNWTO) data indicates that there were around 69.8 million international tourist arrivals in 2020, which increased to around 82.9 million, showing a growth of nearly 18% increase in the Americas, of which around 69% belong to the North American region only indicating its dominance over other American regions.
Moreover, the growing senior population in this region is another reason for its dominance over the global motion sickness treatment market. For instance, according to the United Health Foundation 2021 Senior Report, over 54 million adults ages 65 and older living in the United States in 2021, making upto 16.5% of the nation's population total number is predicted to reach 85.7 million making upto 20% of the overall U.S. population by 2050. Thus from the mentioned data, it is anticipated that North America will dominate the global motion sickness treatment market throughout the forecast period.
Motion Sickness Treatment Market Competitive Landscape
Motion sickness treatment is moderately competitive due to local and global key market players. A few market players are Prestige Brands, Inc., Baxter International, Inc., GlaxoSmithKline plc, Myungmoon Pharm Co. Ltd., WellSpring Pharmaceutical Corporation, Caleb Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Pfizer, Relifeband Technologies, and CVS Health. These key market players contribute to the global motion sickness treatment market growth through various market tactics. For instance, in August 2022, GSK acquired Affinivax, Inc., a clinical-stage biopharmaceutical company.
Prestige Consumer Healthcare Inc.
Overview:
Prestige Consumer Healthcare Inc. is involved in manufacturing and distributing over-the-counter healthcare and household cleaning products and drugs. Prestige Consumer Healthcare Inc. was formed in 1996 by merging Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company and is headquartered in Tarrytown, New York.
Product Portfolio:
The product portfolio of Prestige Consumer Healthcare Inc. for motion sickness treatment has Dramamine: Which is an antihistamine used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness.
The global motion sickness treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.